Individual short-acting opioids and the risk of opioid-related adverse events in adolescents.
Cecilia P ChungStephen Todd CallahanWilliam O CooperWilliam D DupontKatherine T MurrayAndrew D FranklinKathi HallJudith A DudleyCharles Michael SteinWayne A RayPublished in: Pharmacoepidemiology and drug safety (2019)
In adolescents without cancer or other severe conditions prescribed short-acting opioids, the incidence of both all opioid-related adverse events and more serious events with opioid-related escalation of care, hospitalization, or death was consistently greater for tramadol than for hydrocodone.